Navigation Links
Some Elderly Heart Failure Patients Get Little Help From Meds, Study Finds

Experts say new drugs and guidelines are needed to treat diastolic dysfunction,,,,

THURSDAY, March 12 (HealthDay News) -- Elderly people suffering from a type of heart disease called diastolic heart failure do not seem to benefit from the commonly prescribed heart failure drugs, researchers from Cedars-Sinai Medical Center in Los Angeles report.

As the population in the United States ages, more elderly people are being treated for heart failure. But even though they make up the majority of those treated for the disease, little is known about the effectiveness of treatment, researchers say.

"We really don't have many data on heart failure patients above the age of 80," said lead researcher Dr. Ernst R. Schwarz, medical director of the Cardiac Support Program and co-director of the Heart Transplant Program at the Cedars-Sinai Heart Institute.

In their study, the researchers looked at elderly people with diastolic dysfunction. In this condition, the systolic function of the heart is normal. "That means their pump function is normal, but their relaxation is impaired," Schwarz explained.

Diastolic dysfunction is common, affecting 50 percent of all heart failure patients, Schwarz said. It is highly prevalent among the elderly and among women, but often it is not diagnosed and not effectively treated, he said.

"We really don't know how to treat these patients because the guidelines from the American Heart Association and the American College of Cardiology are based on systolic heart failure," Schwarz said. "We do not have dedicated guidelines on the treatment of diastolic heart failure."

The report is published in the March 15 issue of the American Journal of Cardiology.

For the study, Schwarz's team studied 142 people with heart failure, who averaged 87 years old. During five years of follow-up, 69 percent of them died.

The researchers found that none of the usually prescribed drugs -- including statins, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, beta blockers, diuretics, calcium channel blockers, nitrates and digoxin -- seemed to make any significant difference in who survived and who died.

"At least for patients above the age of 80 with diastolic heart failure, whether they are treated or not with these kind of medications does not affect their mortality or their long-term outcome," Schwarz said.

Dr. Byron Lee, a cardiologist and assistant professor of medicine at the University of California, San Francisco, appeared skeptical of the findings.

"I would be very cautious when drawing conclusions from this study," Lee said. "This is not a randomized, controlled study. The patients on the cardiovascular drugs might have been much sicker than the comparison group. Therefore, the drugs may have actually had a big impact -- keeping the sicker patients alive as long as the ones not on heart medications."

Schwarz, however, speculated that lower doses of the drugs might be appropriate for people with diastolic heart failure. In any case, he said, more research is needed, as are better treatment guidelines.

"We really don't have a clue how to treat them and how to treat them better," Schwarz said. "We are at the beginning of a learning curve to try to understand the changes in the elderly organism, which might require more caution with certain drugs, more dose adjustments. We need too look at the very elderly patient in a different way."

Dr. Gregg C. Fonarow, a professor of cardiology at the University of California, Los Angeles, said that better treatments need to be found for people suffering from diastolic heart failure.

"Patients who have heart failure with preserved systolic function represent half of the 5 million patients with heart failure in the United States," Fonarow said. "These patients face substantial risk for morbidity and mortality."

Although a number of cardiovascular medications reduce mortality in people with heart failure and reduced systolic function, no medical therapy has yet shown, in randomized clinical trials, to reduce risk in people with diastolic heart failure, Fonarow said.

"There is a critical need for more research and clinical trials to identify therapies which will be effective in patients with heart failure and preserved systolic function," he said.

More information

The American Heart Association has more on heart failure.

SOURCES: Ernst R. Schwarz, M.D., Ph.D., professor, medicine, Cedars-Sinai Medical Center, medical director, Cardiac Support Program, and co-director, Heart Transplant Program, Cedars-Sinai Heart Institute, Los Angeles; Gregg C. Fonarow, M.D., professor, cardiology, University of California, Los Angeles; Byron Lee, M.D., assistant professor, medicine, University of California, San Francisco; March 15, 2009, American Journal of Cardiology

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Gene Tied to Post-Op Delirium in Elderly
2. Chinas 1-child policy could backfire on its elderly
3. Divorce foretells childs future care for elderly parent
4. Brain atrophy in elderly leads to unintended racism, depression and problem gambling
5. Planning for 2020: increasing elderly population poses huge challenges in cancer care
6. NIH scientists describe ways to better assess benefits of influenza vaccine in the elderly
7. Survey reveals ignorance and confusion about cancer amongst the elderly
8. Colorectal cancer screening remains essential for elderly Americans
9. Evotec Reports Positive Top-Line Results in Phase II Study With EVT 201 in Elderly Insomniacs With Daytime Sleepiness
10. Elderly Medicare, Medicaid patients not receiving quality care
11. Most Elderly Dont Get Good Medical Care: Study
Post Your Comments:
Related Image:
Some Elderly Heart Failure Patients Get Little Help From Meds, Study Finds
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
Breaking Medicine Technology: